Chalcogen Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/254.07)
  • Patent number: 10238634
    Abstract: The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 26, 2019
    Assignee: CHEMO RESEARCH, S.L.
    Inventors: Michael T. Nordsiek, Kodumudi S. Balaji
  • Patent number: 10227282
    Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 12, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Menachem Shoham
  • Patent number: 10226423
    Abstract: The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 12, 2019
    Assignee: RxOMEG Therapeutics LLC
    Inventors: Indu Muni, Naomi Vishnupad
  • Patent number: 10213478
    Abstract: The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may be Valley Fever.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 26, 2019
    Assignees: The Translational Genomics Research Institute, Arizona Board of Regents on behalf of Northern Arizona University
    Inventors: David Engelthaler, Elizabeth Driebe, Hongwei “Holly” Yin, Michael Valentine, Donald Chow, Jolene Bowers, Paul Keim
  • Patent number: 10213479
    Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: February 26, 2019
    Assignee: The University of Kansas
    Inventors: Peter S. N. Rowe, Aline Martin, Nicolae Valentin David, M. Laird Forrest, Kenneth Ryan Moulder, Shuang Cai, Daniel J. Aires
  • Patent number: 9968540
    Abstract: The present invention provide compositions and methods for treating a dermatological disorder or disease.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: May 15, 2018
    Assignee: Vapogenix, Inc.
    Inventor: Danguole Spakevicius
  • Patent number: 9918984
    Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 20, 2018
    Assignee: CORTENDO AB (PUBL)
    Inventor: Per Marin
  • Patent number: 9855248
    Abstract: The present invention provides a new crystalline form of itraconazole as well as the method of making same.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 2, 2018
    Assignee: The Chinese University of Hong Kong
    Inventors: Shuai Zhang, Hee Lum Albert Chow, Wai Yip Thomas Lee
  • Patent number: 9795681
    Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 24, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Osvaldo Abreu
  • Patent number: 9650365
    Abstract: Disclosed herein are analogs of itraconazole that are both angiogenesis and hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 16, 2017
    Assignee: UNIVERSITY OF CONNECTICUT
    Inventors: Matthew Kyle Hadden, Upasana Banerjee
  • Patent number: 9636403
    Abstract: A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing such composition includes dissolving the antifungal agent, steroidal anti-inflammatory agent, and acid in dehydrated alcohol, dissolving the antibiotic agent in propylene glycol, combining the two solutions together, heating the combination and then cooling the composition. Several drops of the composition are applied at least twice per day to the affected area of the animal's ear.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: May 2, 2017
    Assignee: Diamondback Drugs of Delaware, L.L.C.
    Inventors: Rory J Albert, Michael R. Blaire
  • Patent number: 9492446
    Abstract: The present invention relates to a method for preparing an itraconazole-containing solid dispersion. The itraconazole-containing solid dispersion according to the preparing method of the present invention has both improved solubility and rapid dissolution rate so that it has an excellent bioavailability. The itraconazole-containing solid dispersion of the present invention is also independent of pH variation of human stomach so that it can minimize the absorption variation of intra- and inter-individuals. In addition, the itraconazole-containing solid dispersion according to the preparing method of the present invention is stable for a long time. The present invention also provides an economical and environment-friendly method for manufacturing an itraconazole-containing composition because the method adds a lactic acid in a solution comprising itraconazole to decrease the amount of an organic solvent needed to dissolve itraconazole.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: November 15, 2016
    Assignees: CTC BIO, Inc.
    Inventors: Hong-Ryeol Jeon, Se-Geun Yu, Bong-Sang Lee, Se-Heum Oh, Jeong-Seo Park, Dong-Ryun Oh, Do-Woo Kwon
  • Patent number: 9198858
    Abstract: The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: December 1, 2015
    Assignee: Watson Pharmaceuticals, Inc.
    Inventors: Michael T. Nordsiek, Kodumudi S. Balaji
  • Patent number: 9095589
    Abstract: Described herein are methods of inhibiting angiogenesis, and treating and preventing disorders associated with angiogenesis by administering anti-angiogenesis compounds to a subject.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: August 4, 2015
    Assignee: Johns Hopkins University
    Inventors: Jun O. Liu, Curtis R. Chong, Jing Xu, Jun Lu, Shridhar Bhat, Wie Shi
  • Publication number: 20150126436
    Abstract: The present invention provides a method of treatment of Scedosporium spp.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 7, 2015
    Applicant: BIODIEM LIMITED
    Inventors: Julie Phillips, Tania Sorrell, Sharon Chen
  • Publication number: 20150099763
    Abstract: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 9, 2015
    Inventors: Stuart James MUDGE, David HAYES, Stefan LUKAS
  • Publication number: 20150094354
    Abstract: A method for treating a cell proliferative disorder in a subject is provided. The method for treating a cell proliferative disorder has a step of: administering a C1GALT1 inhibition substance to the subject for inhibiting C1GALT1 expression or activity in the subject, so as to treat the cell proliferative disorder in the subject.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Min-Chuan HUANG, Yao-Ming WU, Chiung-Hui LIU, Chih-Hsing CHOU, Miao-Juei HUANG, John HUANG, Ji-Shiang HUNG, Chiun-Sheng HUANG, Hsueh-Fen JUAN
  • Publication number: 20150079107
    Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Anna I. Mandinova, Sam W. Lee, Victor A. Neel
  • Patent number: 8975254
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: March 10, 2015
    Assignee: Orion Corporation
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Publication number: 20150064234
    Abstract: It has been discovered that pharmacological inhibition of K+ channels (using the FDA-approved broad-spectrum K+ channel antagonist 4-AP) positively benefitted smn mutant phenotypes, a result that is consistent with the defective excitability of motor circuits by their interneuron or sensory neuron inputs being a critical consequence of SMN depletion. Based on these observations, certain embodiments of the invention are directed to methods of treatment of SMA by administering therapeutically effective amounts of one or more potassium channel antagonists, including 4-aminopyridine, 4-(dimethylamino)pyridine, 4-(methylamino)pyridine, and 4-(aminomethyl)pyridine. Other embodiments are directed to new pharmaceutical formulations comprising two or more potassium channel antagonists.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 5, 2015
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Brian D. Mccabe
  • Publication number: 20150051194
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 19, 2015
    Applicant: RENSSELAER POLYTECHNIC INSTITUTE
    Inventor: Mark P. WENTLAND
  • Patent number: 8957069
    Abstract: The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted bromopiperazine ring; R1 and R2 are the same or different from each other, and represent a hydrogen atom or optionally substituted lower alkyl; R3 and R4 are the same or different from each other, and represent a hydrogen atom or halogenated or non-halogenated lower alkyl; R3 to R7 are the same or different from each other, and represent a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted aromatic heterocyclic ring, optionally substituted amino, or acyl; and represents a single bond or double bond, wherein R2 and R3 do not exist when carbon atoms respectively adjacent to R2: and R3 form a double bond, and there is n
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: February 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Tsukamoto, Takeshi Wakabayashi, Taiichi Ohra
  • Publication number: 20150031707
    Abstract: The present invention relates to a method for manufacturing nano-scale particles of an active material. More particularly, the present invention relates to a method which uniformly mixes a surfactant having an HLB value of 8 or more and a melting point or glass transition temperature of 80° C. or lower and an active material, and mills the mixture using a roller mill, to thereby prepare nanoparticle powder from the active material.
    Type: Application
    Filed: September 21, 2012
    Publication date: January 29, 2015
    Applicant: BIO-SYNECTICS INC.
    Inventors: Kab Sig Kim, Joo Won Park
  • Publication number: 20150017244
    Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 15, 2015
    Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
    Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
  • Publication number: 20150018337
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 15, 2015
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • Publication number: 20150011565
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 8, 2015
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 8921374
    Abstract: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: December 30, 2014
    Assignee: Mayne Pharma International Pty Ltd
    Inventors: Stuart James Mudge, David Hayes, Stefan Lukas
  • Publication number: 20140377384
    Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.
    Type: Application
    Filed: September 14, 2014
    Publication date: December 25, 2014
    Inventor: Giuseppe Trigiante
  • Publication number: 20140364440
    Abstract: The present invention is directed to anti-fungal compositions comprising an anti-fungal agent, an oil and excipients or additives. The compositions of the present invention are devoid of C-11 or greater fatty acids/esters.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 11, 2014
    Inventors: Abhijit S. Bapat, Sudhanand Prasad, Nilu Jain, Nidhi Arora, Gauthami Mahesh, Mallika Mishra, Sumana Ghosh, Suresh Chawrai, Debabrata Mandal
  • Publication number: 20140329832
    Abstract: The present invention provides methods of increasing an amount of a treatment agent in the body, a cancer or tumor. The methods include administering an inhibitor of the metabolic degradation or conversion of the treatment agent to a subject undergoing treatment for a hyperproliferative disorder with said treatment agent. Methods of treating hyperproliferative disorders, tumors and cancers are also provided.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventors: Barry James Maurer, Charles Patrick Reynolds
  • Publication number: 20140322293
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 30, 2014
    Applicant: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Publication number: 20140322327
    Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 30, 2014
    Applicant: UPM-KYMMENE CORPORATION
    Inventors: Antti Laukkanen, Ruzica Kolakovic, Leena Peltonen, Timo Laaksonen, Jouni Hirvonen, Heikki Lyytikainen, Harri Jukarainen, Prijo Kortesuo
  • Publication number: 20140323497
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 30, 2014
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margeiefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • Publication number: 20140315920
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: February 5, 2014
    Publication date: October 23, 2014
    Applicant: HEDGEPATH, LLC.
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • Publication number: 20140315915
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Publication number: 20140308292
    Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).
    Type: Application
    Filed: April 11, 2014
    Publication date: October 16, 2014
    Applicant: Board of Regents of the University of Texas System
    Inventors: Amol Madhusudan Patwardhan, Kenneth Michael Hargreaves, Armen Narakovich Akopian
  • Publication number: 20140309181
    Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
    Type: Application
    Filed: August 28, 2012
    Publication date: October 16, 2014
    Applicant: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
  • Publication number: 20140302103
    Abstract: A hair care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 1500 and mixtures thereof and mixtures thereof or, by weight of said hair care composition; wherein an emulsifier is selected from the group consisting of anionic, non-ionic, cationic, amphoteric and mixtures thereof wherein the average particle size of the pre-emulsified oil in water emulsion is from about 20 nanometers to 20 microns; and a cationic surfactant system wherein the composition is stable with respect to one of the following measures selected from emulsion particle size, viscosity or visual phase separation and mixtures thereof.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: John David CARTER, Qing STELLA, Toshiyuki IWATA, Tanashaya CIENGSHIN, Dariush HOSSEINPOUR, Nobuaki UEHARA, Toshiyuki OKADA, Raymond Xu Zhan TAY
  • Publication number: 20140302132
    Abstract: The present invention relates to processes for the manufacture of suspensions comprising one or more water soluble or water insoluble pharmaceutical or nutraceutical active ingredients with a particle size in the range of from 0.01 to 10 micron. More specifically, suspensions prepared by this process can be used to formulate pharmaceutical compositions, especially in liquid fill capsules.
    Type: Application
    Filed: October 22, 2012
    Publication date: October 9, 2014
    Applicant: M W ENCAP LIMITED
    Inventor: Stephen Brown
  • Publication number: 20140303184
    Abstract: The present invention relates to a process for the preparation of a compound of formula (V), in particular posaconazole, wherein said process comprises the steps of (1) providing a mixture comprising a compound of formula (IV), a protic solvent system, and a suitable base; and (2) heating the mixture of (1) to obtain a mixture comprising the compound of formula (V).
    Type: Application
    Filed: June 14, 2012
    Publication date: October 9, 2014
    Applicant: SANDOZ AG
    Inventors: Thorsten Wilhelm, Martin Langner
  • Publication number: 20140296225
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
    Type: Application
    Filed: October 22, 2012
    Publication date: October 2, 2014
    Inventors: Haifeng Tang, Barbara Pio, Nardos Teumelsan, Alexander Pasternak, Reynalda DeJesus
  • Publication number: 20140296167
    Abstract: A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.
    Type: Application
    Filed: March 3, 2014
    Publication date: October 2, 2014
    Inventors: Hyesook Kim, Sohee Kim
  • Publication number: 20140288032
    Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: DiscoveRx Corporation
    Inventors: Eric J. Kunkel, Evangelos Hytopoulos, Ivan Plavec
  • Publication number: 20140271923
    Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventor: Christopher Brian Reid
  • Patent number: 8835436
    Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: September 16, 2014
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong Yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho Kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
  • Patent number: 8829004
    Abstract: The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: September 9, 2014
    Assignee: Universitaetsklinikum Freiburg
    Inventor: Georg Bauer
  • Publication number: 20140248376
    Abstract: The present invention relates to a composition for the treatment of skin and ear infections in humans and animals such as dogs, cats and horses. In particular, the present invention relates to a topical composition comprising acetic acid, an antibacterial and/or an anti-fungal, and preferably also an anti-inflammatory. More specifically, the composition of the present invention is a bandage, bedding, clothing, conditioner, cream, drape, dressing, film, foam, gauze, gel, lotion, mousse, otic solution, pad, patch, serum, shampoo, solution, spray, or wipe for treatment or prevention of skin infections, wherein the composition comprises about 0.1-10% acetic acid, about 0.1-10% boric acid, about 0.01-20% azole, and optionally about 0.01-20% corticosteroid.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: DECHRA VETERINARY PRODUCTS, LLC
    Inventor: Steven A. MELMAN
  • Publication number: 20140234225
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2014
    Publication date: August 21, 2014
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Christian F. Wertz, Niels P. Ryde
  • Publication number: 20140228334
    Abstract: Process for producing composite materials by reactive spray-drying, where a liquid phase A, which comprises inorganic cations, and a liquid phase B, which comprises anions which, with the inorganic cations, form a salt that is insoluble in the mixture of the liquid phases are sprayed together using at least one multi-substance nozzle, and where at least one hydrophobic active ingredient is present in dissolved form in at least one liquid spraying phase, and where the salt formed from the cations of phase A and the anions of phase B has a solubility of less than 0.02 mol/l in the neutral aqueous medium.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: BASF SE
    Inventors: Andreas Kempter, Max Siebert, Heidrun Debus
  • Publication number: 20140219929
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov